<DOC>
	<DOCNO>NCT00693849</DOCNO>
	<brief_summary>The aim study identify genetic , physical ( brain ) psychological ( cognitive ) marker ( combination ) predict specific response range antidepressant treatment ( Escitalopram , Venlafaxine , Sertraline ) patient diagnose major depressive disorder . This study focus outcome may impact `` personalised medicine '' implement depression .</brief_summary>
	<brief_title>International Study Predict Optimised Treatment - Depression</brief_title>
	<detailed_description>This open-label , randomise ( effectiveness ) study ( ie . comparison active treatment ) identify genetic marker , brain function , brain structure , psychological cognitive indicator ( combination marker ) MDD subject versus healthy control . Approximately 2,016 subject major depressive disorder ( MDD ) across multiple international site ( USA , Canada , UK , South Africa , New Zealand , The Netherlands Australia ) randomise one three approve effective treatment arm : Treatment A Escitalopram . Treatment B Sertraline . Treatment C Venlafaxine XR . A group match healthy control ( n = 672 ) also enrol . Subjects ask attend test facility two separate occasion ; Pre-treatment ( Pre-Tx ) 8 week post initiation treatment . The assessments/procedures Pre-Tx Week 8 include : Baseline clinical work-up , blood collection genetic analysis , cognitive test electrical brain functioning ( EEG/ERP ) . Structural functional data MRI data collect ten percent ( 10 % ) participant . On Day 4 Weeks 2 , 4 , 6 , 12 , 16 , 24 52 Subjects contact phone ask complete 2 questionnaire via internet .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Meet DSMIV criterion primary diagnosis MDD . HAMD17 score â‰¥ 16 . 1865 year agerange Subjects English Dutch literacy fluency . Written , inform consent . Presence suicidal ideation and/or tendency ( determine score &gt; 12 Section C , Suicidality , MINI Plus ) , Bipolar IIII , psychosis , primary eating disorder , Post Traumatic Stress Disorder ( PTSD ) , Obsessive Compulsive Disorder ( OCD ) , PostNatal Depression well Axis II personality disorder diagnose use MINI Plus health care professional . Pregnancy woman child bear potential take medically accept form contraception risk become pregnant study . Breastfeeding . Known contraindication intolerance use Escitalopram , Sertraline Venlafaxine XR define product package insert drug ( include previous treatment failure high recommend dose ) . Use psychological counselling therapy antidepressant/CNS drug wash prior participation eliminate Week 8 discontinuation . Use medication know contraindicated Escitalopram , Sertraline , Venlafaxine XR ( refer product package insert drug ) . Known medical condition , disease neurological disorder might , opinion investigator/s , interfere assessment make study put subject increase risk expose optimal dos drug treatment . History head injury loss consciousness least 10 minute . Recent/current substance dependence ( defined Section K Mini Plus per 6 month period and/or alcoholism ) past six month . Participation investigational study within four month baseline visit subject receive experimental drug/device could affect primary end point study . Subjects , opinion investigator , severe impediment vision , hear and/or hand movement , likely interfere ability complete test battery . Subjects , opinion investigator , unable and/or unlikely comprehend follow study procedure instruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>CNS</keyword>
	<keyword>iSPOT</keyword>
	<keyword>MDD</keyword>
</DOC>